Clinical Trial Update: A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating the combination of nivolumab with ADG106 in metastatic non-small cell lung cancer is in Phase 1/2, with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non Small Cell Lung Cancer

Drugs mentioned

• ADG106
• nivolumab (nivolumab)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Metastatic Non Small Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN